Conor Barry
Vice President & Global Head, Bioconjugate & Large Molecule R&D Piramal Pharma Solutions
Seminars
Wednesday 10th March 2027
Evaluating Phase & Product Appropriate Bioconjugate Development
8:30 am
- Exploring the differing development approaches of ADCs across the preclinical to commercial spectrum
- Understanding how the bioconjugate landscape now encompasses a wide variety of modalities with differing mechanisms of action and molecular structures
- Exploring relevant examples of how the requirements for process and analytical development can vary between different conjugates
